“New Antiseizure Medication Shows Promise for Treating Severe Epilepsy in Long-Term Study”

Byeeadmin

In a recent study, researchers explored the long-term effects of a new antiseizure medication called Perampanel (PER) in patients suffering from developmental and epileptic encephalopathies (DEEs). DEEs are complex conditions characterized by severe seizures, abnormal brain wave patterns, and developmental delays, often making them difficult to treat. This particular study included 24 patients who had been on PER for five years, analyzing their seizure frequency and any side effects they experienced.

The findings showed that PER was quite effective in reducing seizure frequency across various types of seizures. At the five-year mark, about 33% of patients experienced a reduction in seizures by more than 50%. The effectiveness varied by seizure type, with generalized tonic-clonic seizures (GTCS) and myoclonic seizures showing the best response rates, at around 54–55%. While these results are promising, 70% of the participants also reported experiencing side effects, which primarily included feelings of drowsiness or emotional changes like irritability. Fortunately, most of these side effects were mild and manageable.

What’s particularly interesting about PER is how it works. Unlike many traditional antiseizure drugs, which target specific pathways, PER inhibits a receptor involved in the brain’s communication process, potentially leading to a more balanced seizure control. This could provide a significant advantage for patients with DEEs, as treatment options are often limited, and the search for effective therapies continues to be a pressing issue.

Despite these positive results, the study had some limitations, such as a small sample size and a lack of long-term monitoring for subclinical seizures. These factors mean more research is needed to fully understand PER’s efficacy and safety in a broader population. However, given the complexity of DEEs and the challenges they present, the initial findings make PER a noteworthy option for patients facing these difficult conditions.

In summary, this research suggests that Perampanel could be an effective long-term treatment option for patients with DEEs, providing hope for those enduring the challenges of severe and hard-to-treat seizures.

-- This post was originally published on this site

Similar Posts

“Long-Term Study Shows Lacosamide May Help Control Seizures in People with Generalized Epilepsy”

Byeeadmin

A recent long-term clinical trial explored the safety and effectiveness of lacosamide (LCM) as an additional treatment for people suffering from generalized-onset tonic-clonic seizures (GTCS), particularly those with idiopathic generalized epilepsy (IGE). This study, known as EP0012, involved 239 participants aged four years and older, and it provided a look into how well LCM could help manage seizures over an extended period—up to five years for children and two years for adults.

“Exploring Neurobehavioral Therapy for Seizures in Traumatic Brain Injury Patients”

Byeeadmin

Traumatic brain injuries (TBI) can lead to various complications, including seizures, which can be either functional (non-epileptic) or epileptic. Unfortunately, treatments for these seizure conditions in TBI patients are limited, prompting researchers to explore the effectiveness of a specific therapy called neurobehavioral therapy (NBT). In a new study, scientists looked into how well NBT worked for patients dealing with both TBI and seizures over the course of a year.

“New Study Examines Long-Term Benefits of Perampanel for Managing Severe Epilepsy in Children and Adults”

Byeeadmin

A recent study explored the long-term effects of a medication called perampanel for patients with Lennox–Gastaut syndrome (LGS), a severe form of epilepsy that often leads to frequent, uncontrolled seizures. The study involved patients aged two and older, all of whom were already on one to four other epilepsy medications but still experiencing at least two significant seizure episodes, known as “drop seizures,” each week. Researchers wanted to assess whether adding perampanel could help reduce those drop seizures over a long period.

“Study Reveals Impact of Non-Recommended Epilepsy Medications on Patient Care”

Byeeadmin

A recent study set out to explore how well the treatment guidelines for epilepsy are being followed, specifically looking at the impact of using non-recommended antiseizure medications (ASMs) on healthcare utilization. Epilepsy, a neurological disorder that causes seizures, is commonly treated with ASMs, but not all medications are equally effective or safe. Researchers focused on adults who had just been diagnosed with epilepsy between 2015 and 2019, and they analyzed their treatment patterns and subsequent healthcare needs.

“New Study Explores Risks of Stopping Seizure Medications During Early Pregnancy”

Byeeadmin

A recent study from China has shed light on the effects of withdrawing antiseizure medications (ASMs) during the first trimester of pregnancy, which is a critical period for both the mother and the developing fetus. The research involved a substantial number of pregnancies—695 to be exact—tracked across 50 hospitals from 2009 to 2023. The main aim was to understand how stopping these medications might impact seizure control and the health of the offspring.